ncRNA basic information
ncRNA ID:
MI0003126
ncRNA Database:
miRBase
ncRNA Name:
miR-491
ncRNA Type:
miRNA
ncRNA Expression:
up-regulated
ncRNA Method:
RT-PCR,RT-qPCR
ncRNA Target Gene:
CRYAB
ncRNA Pathway:
NA
Evidence (ncRNA-drug):
validated
drug basic information
Drug ID:
DB00515 (APRD00359)
Drug Name:
Cisplatin
Drug Method:
In the present study, we investigate the clinical significance of serum miR-491 level and the potential role of miR-491 in OS lung metastasis and chemoresistance. Clinical data show that the level of miR-491 was decreased in serum from OS patients compared with healthy control subjects, and that a decreased serum miR-491 level is correlated with increased metastasis, poor chemoresponse, and lower survival rate in OS patients. In vitro and in vivo experiments show that overexpression of miR-491 suppresses OS cell lung metastasis, whereas it enhances cisplatin (CDDP)-induced tumor growth inhibition and apoptosis. In contrast, inhibition of miR-491 stimulates OS cell lung metastasis and suppresses CDDP-induced tumor growth inhibition and apoptosis. Furthermore, we demonstrate that miR-491 exerts its role by directly targeting alphaB-crystallin (CRYAB) in OS.
Drug Response:
sensitive
Cancer basic information
Cancer:
osteosarcoma
Tissue/Cell:
cell line (MG63, Saos-2, and U2OS )
Other information
Title:
miR-491 Inhibits Osteosarcoma Lung Metastasis and Chemoresistance by Targeting alphaB-crystallin.
Journal:
Mol Ther
Published:
2017
PubMed ID:
28648665